Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H15F3N4O3.C7H8O3S.H2O |
Molecular Weight | 594.56 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC=C(C=C1)S(O)(=O)=O.NC2CCN(C2)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=C(F)C=C(F)C=C5)C(O)=O
InChI
InChIKey=SSULTCPIIYRGFQ-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3.C7H8O3S.H2O/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;1-6-2-4-7(5-3-6)11(8,9)10;/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);2-5H,1H3,(H,8,9,10);1H2
Molecular Formula | C7H8O3S |
Molecular Weight | 172.202 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H15F3N4O3 |
Molecular Weight | 404.3426 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf
Curator's Comment: description was created based on several sources, including:
http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf
Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 |
|||
Target ID: CHEMBL2363076 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date6.3296641E11 |
|||
Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date6.3296641E11 |
|||
Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date6.645024E11 |
|||
Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date6.3296641E11 |
PubMed
Title | Date | PubMed |
---|---|---|
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. | 1996 Nov |
|
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. | 1996 Oct |
|
[In vitro anti-MAC activities of new quinolones in focus (2)]. | 1996 Sep |
|
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. | 1999 Oct |
|
The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. | 2000 Jul |
|
History of quinolones and their side effects. | 2001 |
|
Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate. | 2001 Dec |
|
In vitro method for prediction of the phototoxic potentials of fluoroquinolones. | 2001 Dec |
|
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species. | 2002 Mar |
|
Clinical assessment of tosufloxacin tosilate. | 2002 Mar |
|
Pharmacokinetics and safety assessment of tosufloxacin tosilate. | 2002 Mar |
|
Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin. | 2002 Mar |
|
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. | 2002 Mar |
|
Alteration of constitutive apoptosis in neutrophils by quinolones. | 2003 Jun |
|
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. | 2004 Apr |
|
An unusual form of crystal-forming chronic interstitial nephritis following long-term exposure to tosufloxacin tosilate. | 2004 Nov |
|
[Study on the accumulation of fluoroquinolones in clinical isolates of susceptible and multi-drug-resistant Escherichia coli strains]. | 2005 Jan |
|
Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. | 2005 Jul |
|
Antimicrobial safety: focus on fluoroquinolones. | 2005 Jul 15 |
|
In vitro activity of fluoroquinolones against Mycoplasma genitalium and their bacteriological efficacy for treatment of M. genitalium-positive nongonococcal urethritis in men. | 2005 Nov 1 |
|
[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. | 2006 Dec |
|
[Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibiotics in Gifu prefecture (2004)]. | 2006 Jun |
|
[Effectiveness of switch therapy for peritonitis]. | 2007 Aug |
|
[Susceptibility of clinical isolates from primary care clinics to oral antibacterial agents]. | 2007 Feb |
|
Tosufloxacin tosilate-induced thrombocytopenic purpura. | 2007 Jul |
|
[A case of acute bronchitis caused by Neisseria meningitidis associated with HIV infection]. | 2007 Nov |
|
[Sensitivity surveillance of Haemophilus influenzae isolates for several antibiotics in Gifu Prefecture (2006)]. | 2008 Aug |
|
Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. | 2008 Jul |
|
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. | 2008 Jun |
|
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. | 2009 |
|
Fluoroquinolones reduce carrageenan-induced edema in rats and the involvement of the glucocorticoid receptor system. | 2009 Apr |
|
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | 2009 Dec 2 |
|
Corneal deposits after topical tosufloxacin in a patient with poor tear secretion. | 2009 Jan |
|
Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. | 2009 Jun 18 |
|
[Efficacy of tosufloxacin in genital chlamydial infections]. | 2009 Oct |
|
[Antibiotic susceptibility of blood-borne Streptococcus pneumoniae and efficacy assessment of respiratory quinolones using Monte Carlo simulation]. | 2010 Feb |
|
Legionella pneumophila induces cathepsin B-dependent necrotic cell death with releasing high mobility group box1 in macrophages. | 2010 Nov 22 |
|
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. | 2010 Sep 20 |
Patents
Sample Use Guides
In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Osteomyelitis, arthritis: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 3 times a day. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Typhoid/paratyphoid fever: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 4 times a day for 14 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28288170
The MIC90s of tosufloxacin among the 27 isolates of macrolide-resistant Mycoplasma pneumoniae (MRMP) was 0.25 ug/ml and those among the 23 isolates of macrolide-sensitive Mycoplasma pneumoniae (MSMP) was 0.5 μg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:36:34 UTC 2023
by
admin
on
Sat Dec 16 04:36:34 UTC 2023
|
Record UNII |
5L69LG8ZDQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000164913
Created by
admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
|
PRIMARY | |||
|
SUB179549
Created by
admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
|
PRIMARY | |||
|
32248
Created by
admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
|
PRIMARY | |||
|
1400591-39-0
Created by
admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
|
PRIMARY | |||
|
5282468
Created by
admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
|
PRIMARY | |||
|
5L69LG8ZDQ
Created by
admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |